Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | ITK | Q08881 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | MMP14 | P50281 | 1/20 | 0.30 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.30 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171455 | 0.91 | GRM2 (0.38) | GRM2KDM4EALDH1A1GLAGAA | |
| SCHEMBL12441180 | 0.89 | GRM2 (0.50) | GRM2KDM4EALDH1A1GLAGAA | |
| SCHEMBL12441128 | 0.89 | GRM2 (0.50) | GRM2KDM4EALDH1A1GLAGAA | |
| SCHEMBL12441190 | 0.89 | GRM2 (0.38) | GRM2KDM4EALDH1A1GLAGAA | |
| SCHEMBL12441120 | 0.89 | GRM2 (0.38) | GRM2KDM4EALDH1A1GLAGAA | |
| SCHEMBL12441187 | 0.89 | GRM2 (0.38) | GRM2KDM4EALDH1A1GLAGAA | |
| SCHEMBL1765563 | 0.86 | CYP11B2 (0.39) | GRM2KDM4EALDH1A1GLAGAA | |
| SCHEMBL12441129 | 0.85 | GRM2 (0.35) | GRM2KDM4EALDH1A1GLAGAA | |
| SCHEMBL2220917 | 0.85 | GRM2 (0.35) | GRM2KDM4EALDH1A1GLAGAA | |
| SCHEMBL7926084 | 0.83 | KDM4E (0.38) | GRM2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346334-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20110178117-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178117-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2010036544-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178117-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | GRM2, GRM1, GRM3 | GRM2 1/4885KDM4E 2667/4885ALDH1A1 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.